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Objectives: To assess the treatment of venous thromboembolism (VTE) in hospitalized patients enrolled in a national,
multicenter database.
Methods: This was a retrospective, cohort study that randomly selected VTE patients from 38 academic/teaching,
community, and Veterans Administration (VA) hospitals. The study included a physician survey component. The patients
selected were those treated between January 2002 and June 2003 who had an ICD-9-CM code for pulmonary embolus
(PE), deep vein thrombosis (DVT), or pregnancy-related PE or DVT.
Results: The study included 939 patients: 52.7% with DVT, 28.4% with PE, and 18.8% with PE and DVT. Mean age was
59.5 years. Risk factors included obesity (bodymass index>30) in 30.1%, history of VTE in 28.0%, malignancy in 27.4%,
surgery in 21.1%, and immobility in 18.5%. Only 56.1% of patients were treated with low-molecular-weight heparin
(LMWH). Bridging from LMWH or unfractionated heparin (UFH) to warfarin was completed during hospitalization in
486 (68.6%), but only 246 (50.6%) had an international normalized ratio (INR)>2 for 48 hours before discontinuation
of the injectable anticoagulant. Length of stay in patients discharged on bridge therapy was 4.0  3.7 days vs 8.1  5.8
days for patients discharged on warfarin therapy (P < .001). Ninety-two (10.1%) patients were discharged with neither
oral nor injectable anticoagulation and had a mean duration of treatment of only 10.6  16.2 days. Of 245 physicians
surveyed from participating hospitals, 84% and 53%, respectively, indicated that LMWH was their preferred agent for
treatment of DVT and treatment of PE.With regard to warfarin, 30% did not believe it was necessary to have a therapeutic
INR for >2 days before discontinuing LMWH or UFH, and 27% responded that it was necessary to keep DVT patients
in the hospital until they were therapeutic.
Conclusions: In this cross-section of United States hospitals, lower than anticipated use of LMWH, insufficient
bridging from UFH or LMWH to warfarin, and continuation of anticoagulation after hospitalization were all
problems discovered with the treatment of VTE. Physician knowledge, attitudes, and beliefs are partially responsible
for the gap between actual practice and international guidelines. These results suggest that hospitals should evaluate
their adherence to international VTE treatment guidelines and develop strategies to optimize antithrombotic
therapy. ( J Vasc Surg 2005;42:726-33.)Venous thromboembolism (VTE), including pulmo-
nary embolism (PE) and deep vein thrombosis (DVT), is a
serious medical complication, with an annual United States
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726(US) incidence of approximately 200,000 cases.1 One-year
survival after VTE has been reported to be as low as 63.6%,
with 1-year survival for DVT at 85.4% and 47.7% for PE
with or without DVT.2
Treatment for VTE has been widely studied, and treat-
ment guidelines have been published and frequently up-
dated by the American College of Chest Physicians (ACCP),
American College of Emergency Physicians, Eastern Asso-
ciation for the Surgery of Trauma, and Institute for Clinical
Systems Improvement.3 Generally, acute treatment con-
sists of low-molecular-weight heparin (LMWH) or unfrac-
tionated heparin (UFH) for 4 to 5 days, with overlapping
therapy to warfarin until an international normalized ratio
(INR) of 2 for two consecutive days is achieved. Antico-
agulation should be continued for at least 3 to 12 months,
depending on the site of thrombosis and risk factors.4,5
Failure to provide adequate VTE treatment can result in
patient morbidity and mortality, with a substantial eco-
nomic burden.6
Recent data show that practitioners follow evidence-
based guidelines inconsistently in a wide variety of disease
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performed to compare anticoagulation treatment strategies to
evidence-based guidelines (ACCP 2001) over a broad cross-
section of US hospitals.4 However, modest changes in re-
cently published guidelines (ACCP 2004) are highlighted.5
In addition, physicians were surveyed to determine their
knowledge, attitudes, and beliefs concerning treatment.
Results were provided to participants for quality improve-
ment and to provide a stimulus for improving antithrom-
botic management, where needed.
METHODS
Cohort study. This research was based on data from
the National Anticoagulation Benchmark and Outcomes
Report (NABOR) (EPI-Q, Inc, Oakbrook Terrace, Ill), a
retrospective cohort study. NABOR was designed to eval-
uate anticoagulation practices among participating US hos-
pitals and to collect quality improvement data for partici-
pating sites.
Participants were identified from referrals provided by
professional societies, including the American College of
Chest Physicians, the American Venous Forum, and the
American Society of Health-System Pharmacists. Hospitals
were recruited according to geographic location and insti-
tution type. We attempted to recruit 40 hospitals com-
prised of five Veterans Administration (VA) hospitals and
an equal number of academic/teaching and community
hospitals. To be eligible, hospitals were expected to obtain
all site-mandated approvals from their respective review
committee(s) and to abstract data 90 days. Seventy-five
hospitals were approached for inclusion, with the first 40
responding hospitals selected. Two hospitals were not able
to collect and submit data and subsequently withdrew.
The study period encompassed January 2002 through
June 2003. To meet the targeted sample of 25 cases per
site, one site was given a waiver to include patients before
January 2002. Sites identified VTE patients discharged dur-
ing the interval with the following ICD-9-CMcodes: 415.11-
415.19 (PE), 453.8 (DVT), 673.2-673.8 (pregnancy-related
PE), and 671.00-671.9 (pregnancy-related DVT). Patients
18 years old or those admitted from or discharged to
another hospital were excluded. Each site used a random
number-generated table to select the 25 VTE cases.
Trained data collection personnel performed a medical
record review at each site and abstracted data by using a
standard data collection form and data dictionary. Personnel
entered data into NABOR software for de-identification of
personal information and for partial data validation. The
data collection tool included patient demographics, VTE
event(s), comorbidities, acute and secondary VTE treat-
ment, VTE risk factors, in-hospital complications, and
postdischarge emergency department visits or rehospital-
ization 30 days of discharge. Major hemorrhage was
defined as an intracranial bleed or retroperitoneal bleed.
Minor hemorrhage was defined as epistaxis, ecchymosis,
hematoma, or microscopic hematuria. Any missing or in-consistent variables were resolved before transmission to
the study center. Upon receipt, the study center reviewed
the data for inconsistencies. Queries were resolved with
each site before data analysis.
Physician Knowledge Attitudes, Beliefs, and Prac-
tices (KABP) Survey. Participating hospitals were asked
to provide the study center with a physician directory from
which randomly to select names of physicians involved in
VTE care. Physician specialties were internal medicine,
cardiology, orthopedic surgery, family practice, and emer-
gency medicine. Physicians were contacted by e-mail,
phone, or office fax and invited to participate in the survey.
The survey was competed either on-line, or by return fax
for physicians without Internet access. To be included in
the analysis, physicians must have reported treating 5
cases of VTE within the past 12 months. Respondents
provided their specialty, gender, number years in practice,
and board certification. They were asked to respond either
with agree, disagree, or uncertain to a series of questions
regarding anticoagulant selection preference, perceived ef-
fectiveness of available agents, practice regarding bridging
from injectable to oral agents, risk of complications related
to therapy, and attitudes regarding patient self manage-
ment of therapy postdischarge.
Analysis. Descriptive analysis of the clinical cohort
data was performed to examine the distribution of charac-
teristics among VTE patients and the treatment profile of
these patients across different hospitals. Univariate analyses
were used on the basis of the preliminary descriptive statis-
tics. The relationship between treatment profile and clinical
outcomes was examined. Differences were assessed with
either the 2 test or Fisher’s exact test for categoric vari-
ables, and the Mann-Whitney U test for non-normally
distributed continuous variables. Analysis of the survey
results was descriptive, with frequency of responses re-
ported for each survey item. This study was performed in
2003, before the publication of 2004 ACCP guidelines.
Therefore, we examined two indicators for the discontinu-
ation of LMWH or UFH, namely an INR 2.0 for two
consecutive days and 4 days of overlapping (bridge) ther-
apy, which is in the 2001 ACCP guidelines vs at least 5 days
of concomitant LMWH or UFH, which is in the 2004
ACCP guidelines.4,5
RESULTS
Cohort study. The benchmark database included 939
patient records representing 38 hospitals (21 academic/
teaching hospitals, 13 community hospitals and 4 VA hos-
pitals) from 27 states. A total of 826 patients (88.0%) were
admitted for VTE, and 113 patients (12.0%) experienced
the event during hospitalization.
Isolated DVT was identified in 495 patients (52.7%);
isolated PE was identified in 267 (28.4%); and 177 patients
(18.8%) had both PE and DVT. The average age was 59.4
17.6 years and the ratio of men to women was 49.0:51.0.
The most frequently identified risk factors were obesity
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(28.0%), malignancy (27.4%), surgery within the past 30
days (21.1%), and immobility 72 hours (18.5%) (Table I)
Idiopathic VTE occurred in 37.4% of the patients. Thirty-
two patients died during hospitalization, resulting in a
mortality rate of 3.4%. The mortality rate in those with
isolated DVT was 2.2%, isolated PE was 5.6%, and both PE
and DVT was 3.4%.
Acute treatment. For acute VTE treatment, 562 pa-
tients (59.9%) received UFH, 527 patients (56.1%) re-
ceived LMWH, 78 patients (8.3%) received adjusted-dose
subcutaneous UFH, 6 patients (0.6%) received a direct
thrombin inhibitor (Table II), and 260 patients (27.7%)
received two or more of these treatment categories. Fifty-
two patients were not treated with injectable therapy and
only received warfarin during hospitalization.
Internists were involved in the care of 618 patients
(65.8%), emergency department physicians treated 249
(26.5%), surgeons treated 101 (10.8 %), cardiologists treated
148 (15.8%), oncologists treated 100 (10.6%), and family
practitioners prescribed anticoagulation in 70 patients
(7.5%). Other specialists, including pharmacists and nurse
practitioners, prescribed anticoagulation in 234 patients
(24.9%). For 389 patients (41.4%), two or more specialties
were involved in the prescription of anticoagulation during
their hospital stay.
Use of warfarin with or without bridge therapy.
Seven hundred sixty patients (80.9%) received warfarin
during hospitalization. Of those, 709 patients (93.3%)
received bridge therapy (UFH or LMWH plus warfarin)
before discharge, and the remaining 51 patients did not.
The injectable agent, either UNF or LMWH, was discontin-
ued in 486 patients (68.6%) during hospitalization.However,
only 246 (50.6%) of these had obtained an INR value2.0
for 48 hours before the injectable agent was discontinued.
Of the remaining 240 patients with an INR 2 for 48
hours before injectable agent was discontinued, only 74
(30.8%) had received at least 4 days of bridge therapy. The
mean duration of bridge therapy in those who achieved a
Table I. Venous thromboembolism risk factors
Total patients
N  939
Incidence
n (%)
Obesity (BMI 30) 283 (30.1)
Previous VTE 263 (28.0)
Malignancy 257 (27.4)
Surgery 90 days 198 (21.1)
Immobility 72 hours 174 (18.5)
Congestive heart failure 100 (10.6)
Previous stroke, TIA, or systemic embolus 76 (8.1)
Trauma 54 (5.8)
Oral contraceptive/estrogen use 44 (4.7)
Varicose veins 29 (3.1)
Pregnancy 23 (2.4)
Congenital and acquired thrombophilia 88 (9.4)
BMI, Body mass index; VTE, venous thromboembolism; TIA, transient
ischemic attack.therapeutic INR for 48 hours was 4.5  2.8 days. Themean initiation and discharge daily dose of warfarin
in this group was 6.9  3.0 mg and 5.7  3.1 mg,
respectively.
Patients received warfarin for a mean of 4  4.9 days
before discharge, and the mean discharge INR was 2.0 
1.0. Of the 362 warfarin patients discharged before achiev-
ing an INR value2.0 for 48 hours, only 219 (60.5%) were
discharged on bridge therapy.
Discharge anticoagulation regimen and length of
stay. Of the 907 VTE patients discharged, 72 (7.9%) were
discharged with a prescription for an injectable anticoagu-
lant, 241 (26.6%) with bridge therapy, and 460 (50.6%) with
warfarin (Fig 1). Those discharged on bridge therapy had an
average length of stay (LOS) of 4.0  3.7 days vs 8.1  5.8
days in those discharged on warfarin (P  .001) (Fig 2). An
additional 134 patients (14.8%) received noncontinuous
anticoagulation therapy during their hospitalization and
had a mean LOS of 12.7  17.8 days.
Although PE is usually a contraindication to early dis-
charge, 66 isolated PE patients were discharged on bridge
therapy and had an average LOS of 4.4  3.5 days com-
pared with 133 patients who were discharged on warfarin
and recorded an average LOS of 7.9 4.8 days (P .001).
Likewise, the average LOS for 138 isolated DVT patients
discharged on bridge therapy was 3.6  3.6 days, com-
pared with 228 patients who were discharged on warfarin
and recorded an average LOS of 7.4 5.6 days (P .001).
Ninety-two (10.1%) VTE patients were discharged
without a prescription for oral or injectable anticoagula-
tion; however, these patients only received a mean duration
of treatment of 10.6  16.2 days. In addition, 39 of these
were diagnosed with idiopathic VTE, 33 had malignancy,
and 24 had previous history of VTE. Of 139 patients
discharged to a long-term care facility, 32 (22.9%) had no
discharge anticoagulation orders.
TheLOS in community and academic hospitalswas 6.9
5.8 days and 7.5  9.1 days, respectively, compared with
9.7  13.4 days in VA hospitals. The mean LOS in those
65 years old, 65 to 75 years old, and 75 years old was
Table II. Initial venous thromboembolism treatment*
Total Patients
N  939
(%)
DVT
N  495
(%)
PE
N  267
(%)
PE and DVT
N  177
(%)
LMWH 527 (56.1) 286 (57.8) 147 (55.1) 94 (53.1)
UFH†‡ 562 (59.8) 256 (51.7) 185 (69.3) 121 (68.4)
ADH 78 (8.3) 45 (9.1) 23 (8.6) 10 (5.6)
DTI 6 (0.6) 3 (0.6) 2 (0.7) 1 (0.6)
DVT, Deep vein thrombosis; PE, pulmonary embolism; LMWH, low-
molecular-weight heparin; UFH, unfractionated heparin; ADH, adjusted-
dose subcutaneous heparin; DTI, direct thrombin inhibitor.
*Total exceeds 100% because some patients received more than one treat-
ment. Given the retrospective nature of the study, no determination was
available indicating why patients were switched from one agent to another.
†UFH utilized significantly more in PE vs DVT (P  .001).
‡UFH utilized significantly more in PE and DVT vs DVT (P  .002).7.6  10.2 days, 7.4  6.1 days, and 7.8  6.8 days,
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isolated DVT and 7.7 7.5 days and for patients with PE.
Hemorrhage and VTE recurrence. During hospital-
ization, 79 patients (8.4%) experienced minor hemorrhage
on anticoagulation, and 20 patients (2.1%) had a major
hemorrhage. Of the 760 patients who received warfarin, 68
patients (8.9%) achieved an INR 4. Of these, three pa-
tients (4.4%) experienced a major hemorrhage compared
with nine (1.3%) of those with an INR 4.0 (P  .08).
Patients with an INR 4.0 were nearly three times more
likely to experience a minor hemorrhage than patients with
an INR4.0 (n 12, 17.6% vs n 46, 6.6%) (P .001).
Hospital medical records showed that 22 patients (2.4%)
had a documented emergency department visit or hospital-
ization 30 days of discharge for recurrence of VTE or
another embolic event.
Physician KABP survey. All 38 sites participated in
the survey, with the exception of four VA hospitals. From
the 950 physicians contacted, 315 responses were received
for a 33% response rate. Of these, 246 physicians indicated
treatment of at least five cases of DVT, PE, or both, within
the past year. Most respondents were internists (52%),
followed by emergency physicians (17%), family practitio-
ners (13%), cardiologists (11%), and orthopedic surgeons
Fig 1. Discharge frequency by treatment f(7%). Most were men (75%) and were board certified(75%). Sixty percent had practiced for at least 6 years. With
respect to use of evidenced-based guidelines, 32% indicated
that they followed professional society guidelines, 22%
followed guidelines developed by their institution, and 46%
reported treatment decisions were made on a case-by-case
basis (Table III).
Physician preferences for treatment. Most survey
respondents (82.9%) indicated that LMWH and UFH were
equally effective for managing DVT, which is consistent
with ACCP guidelines (2001, 2004) that recommend
treatment with either agent.4,5 Despite this belief, 84.1%
indicated that LMWH was their preferred agent. Con-
versely, fewer (58.4%) indicated that LMWH and UFH
were equally effective for managing PE and therefore only
52.7% indicated LMWH was their preferred treatment.
ACCP guidelines (2004) state that LMWH is at least as
effective and safe as intravenous UFH in the treatment of
PE and that LMWH is recommended over UFH in patients
with acute nonmassive PE, except in those with severe renal
failure.5
With regard to duration of LMWH or UFH therapy,
only two (65.3%) of three physicians thought that the
duration should be until a therapeutic INR is reached for
two consecutive days. However, 90.6% thought it was safe
7 patients with venous thromboembolism.or 90to send a stable DVT patient home on an injectable anti-
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PE patient home on an injectable anticoagulant. ACCP
guidelines (2004) recommend treatment of DVT as an
outpatient, if possible, but do not make a similar recom-
mendation for the treatment of PE.5
Beliefs and attitudes concerning warfarin. An INR
range of 2.0 to 3.0 was believed to usually be safe care by
92.2% and effective care by 94.3% of the respondents.
Conversely, a subtherapeutic INR range of 1.6 to 1.9 was
believed to usually be safe care by 23.4% and effective care
by only 8.6% of the respondents. Contrary to our study
results, only 27% of survey respondents indicated that it was
necessary to hospitalize a DVT patient until therapeutic on
warfarin. An explanation for this difference between the
study and the survey might be because only 59.2% of
respondents expressed confidence that most patients were
capable of safely taking warfarin. Further, 32.6% indicated
that lack of an anticoagulation monitoring service would
preclude their use of warfarin.
DISCUSSION
The key issues identified in our analysis of the treatment
Fig 2. Length of stay by discharge treatment for 907 pat
difference in length of stay between injectable vs bridge
(P  .001).of VTE were the inadequate treatment overlap of LMWHor UFH with warfarin, a tendency to delay discharge in
isolated DVT patients rather than providing ambulatory
overlapping (bridge) therapy, and inadequate or lack of
treatment postdischarge, especially in those admitted to a
long-term care facility. These are important findings con-
sidering 30-day mortality rates of approximately 6% for
DVT and 12% for PE.8
ACCP treatment guidelines (2004) indicate that DVT
patients should be treated with UFH or LMWH for at least
5 days (compared with 4 to 5 days in 2001 guidelines) and
a vitamin K antagonist until the INR is stable and 2.0
(compared with therapeutic for 2 consecutive days in 2001
guidelines) before discontinuation of UFH or LMWH,
that patients with acuteDVT can be treated with LMWHas
an outpatient; and that a first episode of DVT transient to a
reversible risk factor should receive long-term treatment
greater than 3 months with a vitamin K antagonist.4,5 The
54% self-reported physician use of institutional or profes-
sional society guidelines is likely a significant contributing
factor to the issues identified.
Risk profile. The risk profile of our study population
is similar to that described in other recent studies. Anderson
with venous thromboembolism. *Statistically significant
.01), injectable vs warfarin (P  .01), warfarin vs bridgeients
(P and Spencer9 reviewed 1231 consecutive patients treated
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tive patients with acute DVT confirmed by ultrasound. Our
population’s incidence of major risk factors, including obe-
sity, history of previous VTE, malignancy, major surgery,
and immobility was 30.1%, 28%, 27.4%, 21.1%, and 18.5%,
respectively, compared with Anderson and Spencer with
37.8%, 26%, 22.3%, 11.2%, and 12%, respectively, and
Goldhaber and Tapson with 27%, 22%, 32%, 38%, and 34%,
respectively.
Use of low-molecular-weight heparin. Our data
show only a 56% usage of LMWH in our sample of US
hospitals, despite survey data that indicated it was the
preferred agent for 84% of physicians treating DVT and
58% of physicians treating PE. A recent European registry
found that 88% of patients evaluated received VTE treat-
ment with LMWH.11 Although LMWH has all but elimi-
nated usage of UFH in many parts of Europe,12 our study
demonstrates that US practitioners have been slower to
adopt LMWH, despite evidence that it is as effective and
safe as UFH,13,14 can decrease hospital LOS,15,16 and is
recommended over UFH in 2001 ACCP guidelines.4
Bridging therapy. To our knowledge only one other
study has investigated bridging from heparin to warfarin.
Brandjes et al17 compared acenocoumarol alone vs heparin
and acenocoumarol combined-therapy in the initial treat-
ment of DVT. This randomized, double-blind study was
terminated early because of an excess of both symptomatic
(20% vs 6.7%; P  .58) and asymptomatic (39.6% vs 8.2%;
P .001) events in the group that received acenocoumarol
alone.17
Our bridging data show that only one half of hospital-
ized patients received both heparin and warfarin until the
INR was therapeutic for 48 hours. Seventy percent of those
who were without a therapeutic INR for at least 48 hours
failed to receive at least 4 days of combined therapy. Fur-
ther, only two thirds of physicians surveyed believed it was
necessary to have a therapeutic INR for two consecutive
days before discontinuing LMWH or UFH. Inappropriate
bridging may place patients at risk for increased morbidity
and mortality.
Initially, warfarin may exert a procoagulant effect by
Table III. Responses to Physician Knowledge, Attitude, B
Statement
LMWH is my preferred agent for initial DVT treatment.
LMWH is my preferred agent for initial PE treatment.
LMWH and UFH are equally effective for managing the DVT pa
LMWH and UFH are equally effective for managing the PE patie
It is necessary to have an INR 2.0 for two consecutive days befo
stopping UFH or LMWH.
It is safe to send stable DVT patients home while they are still
receiving an injectable anticoagulant.
It is safe to send stable PE patients home while they are still receiv
an injectable anticoagulant.
LMWH, Low-molecular-weight heparin; DVT, deep vein thrombosis; PE, pdecreasing the anticoagulant proteins C and S more rapidlythan the reduction in clotting factors. In addition, the
initial effect of warfarin is to deplete factor VII, but the
antithrombotic effect of warfarin, caused by depletion of
factors II and X, takes 4 to 6 days to occur.18 Therefore,
thrombus propagation may occur if an immediate-acting
anticoagulant is not given concurrently with warfarin.
Because the induction phase of oral anticoagulation is
unpredictable, we examined the duration of bridge therapy
required to achieve a therapeutic INR range. In a study of
55 DVT patients receiving a warfarin initiation dose of 5
mg, Ageno et al19 found that only 54.4% of patients
reached a therapeutic INR 7 days. Kovacs et al20 found
that only 46% of 97 VTE patients receiving warfarin at an
initiation dose of 5 mg achieved a therapeutic INR 5
days. Our results indicate that approximately 50% of pa-
tients will achieve a therapeutic INR range with a mean
warfarin initiation dose of approximately 7 mg and a mean
duration of 4.5 days of bridge therapy. These findings, as
well as those of others, indicate that at a minimum, 5 days
of bridge therapy is required to achieve a therapeutic INR
range. Many patients will require 5 days of combined
LMWH and warfarin to achieve a therapeutic INR range.
Length of stay. LMWH has been shown to safely and
effectively treat VTE on an outpatient basis, thereby de-
creasing hospital cost.15,21-24 We found a 4-day mean
decrease in LOS in patients discharged on bridge therapy
compared with patients discharged home on warfarin. Se-
gal et al21 in an analysis 3762 patients from eight studies
(three randomized trials and five cohort studies) observed a
3.8-day shorter hospitalization, a median cost savings of
$1600, and similar rates of major bleeding and recurrence
in patients discharged early on LMWH vs those who re-
ceived injectable therapy in the hospital. Only 27.9% of our
isolated DVT population was discharged on bridge ther-
apy, despite 91% of physicians believing it was safe to send
a stable patient home on injectable heparin. This represents
a significant opportunity for patients and providers.
Treatment duration. This study demonstrates that
patients in a broad selection of US hospitals are not receiv-
ing the appropriate duration of anticoagulation therapy for
treatment of VTE. Huisman et al25 found that 51% of
, and Practices survey
Agree n (%) Response Disagree n (%) Uncertain n (%)
206 (84.1) 36 (14.7) 3 (1.2)
129 (52.7) 103 (42.0) 13 (5.3)
203 (82.9) 35 (14.3) 7 (2.9)
143 (58.4) 67 (27.3) 35 (14.3)
160 (65.3) 74 (30.2) 11 (2.9)
221 (90.6) 19 (7.8) 2 (1.6)
154 (63.1) 69 (28.3) 21 (8.6)
nary embolism; UFN, unfractionated heparin.elief
tient.
nt.
re
ing
ulmopatients with symptomatic DVT had asymptomatic PE.
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2004)5; however, controversy exists for treatment of calf
vein thrombosis.26 We found that of 10% of patients not
discharged with anticoagulation, 42% had idiopathic VTE,
36% had malignancy, and 26% had a previous VTE event.
This high percentage may be partially explained by individ-
ual patient refusal of treatment or hospice status. Still,
duration of VTE treatment is important because long-term
sequelae can include fatal PE, post-thrombotic syndrome,
and recurrence.27
Limitations. A potential source of study bias, with
regard to our findings being representative of all US hospi-
tals, was the actual composition of the participating hospi-
tals. Academic facilities comprised 55% of those enrolled. In
addition, we did not record inferior vena cava filter place-
ment or exclude patients discharged to hospice, which
could influence treatment selection and duration of antico-
agulation.
Given the retrospective design of our study, 30-day
complication and mortality rates were limited to readmis-
sion and emergency department records reviewed from the
sentinal hospital. Therefore, actual 30-day mortality and
readmission rates may be understated.
We randomly selected subjects for both the study and
the physician KABP survey, therefore there was not an exact
correlation in the frequency of responses by specialty in our
survey compared with frequency of patients cared for by
specialty in our study. In addition, the survey did not
include physicians from the VA hospital setting.
CONCLUSIONS
We have discovered a significant gap between actual
and evidence-based practice in a cross-section of US hospi-
tals, for which contributing factors are physician knowledge,
attitudes, beliefs, and consistent use of guidelinesOur findings
suggest that hospitals should evaluate their treatment of VTE
and implement performance-improvement initiatives to align
actual practice with evidence-based guidelines. Until more
effective and less complex therapies are available, practitio-
ners must maximize VTE treatment outcomes by appropri-
ately using UFH, LMWH, and warfarin and treating pa-
tients for a duration that will limit recurrence andmortality.
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